Quebec Lung Cancer Screening PLUS Trial

Last updated: August 6, 2025
Sponsor: Nicole Ezer, MD, FRCPC, MPH
Overall Status: Active - Not Recruiting

Phase

N/A

Condition

Scleroderma

Treatment

Educational material and treatment recommendations for patients, general practitioners and pharmacists

Clinical Study ID

NCT05444062
MP-37-2023-8641
  • Ages 55-74
  • All Genders

Study Summary

Does an educational intervention for untreated COPD and cardiovascular disease which is integrated in an existing lung cancer screening program improve guideline concordant medication adherence at 12 months

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patient screened for lung cancer as part of the Quebec Lung Cancer Demonstrationproject by low dose CT scan of the chest.

  • Cardiovascular aim: mild to severe CAC identified on low dose CT, not on guidelinerecommended lipid-lowering therapy.

  • COPD aim: diagnosed with COPD, symptomatic (mMRC >=1 or CAT>= 10) and untreated, ornot on first line guideline recommended therapy for COPD.

Exclusion

Exclusion Criteria:

  • Any participant with a high suspicion of lung cancer, defined as Lung-RADS (LungImaging Reporting and Data System) 3 or 4, as this is an inopportune time toinitiate new medical therapies.

  • Cardiovascular aim: Absent CAC, known clinical atherosclerosis, known former heartsurgery, Diabetes Mellitus.

  • COPD aim: asymptomatic, or already on appropriate first line COPD therapy.

Study Design

Total Participants: 330
Treatment Group(s): 1
Primary Treatment: Educational material and treatment recommendations for patients, general practitioners and pharmacists
Phase:
Study Start date:
April 23, 2023
Estimated Completion Date:
September 30, 2027

Connect with a study center

  • McGill University Health Center

    Montreal, Quebec H3K 2M2
    Canada

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.